Skip to main content

Advertisement

Table 1 Socio-demographic characteristics and clinical profile of the sample ( n = 124)

From: Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample

Variables Frequencies, means and SD Frequencies, means and SD
(Initial sample) (Follow up sample)
First-episode psychosis patients Chronically ill patients First-episode psychosis patients Chronically ill patients
(n= 63) (n= 61) (n= 58) (n= 55)
Socio-demographic data     
 1. Age 27.03 (6.74) 44.80 (12.70)   
 2. Sex     
  Males 34 (54.0%) 34 (55.7%) 30 (51.7%) 30 (54.5%)
  Females 29 (46.0%) 27 (44.3%) 28 (48.3%) 25 (45.5%)
Clinical profile     
 1. Treatment duration 23.06 (15.45) days 20.5 (12.98) years   
 2. BPRSa 23.70 (13.00) 19.05 (8.31) 19.05 (11.00) 16.48 (9.19)
 3. GAFb 52.78 (11.72) 50.38 (12.20) 59.57 (13.38) 51.93 (12.46)
 4. BARSc 0.81 (1.79) 1.36 (2.13) 0.55 (1.52) 2.11 (2.53)
 5. SASc 0.08 (0.28) 0.25 (0.33) 0.08 (0.22) 0.46 (0.50)
 6. AIMSc 0.22 (1.31) 2.59 (5.02) 0.15 (0.77) 3.32 (5.92)
 7. Chlorpromazine equivalent dosage 387.54 (155.51) 646.81 (412.78) 315.28 (140.04) 568.73 (357.97)
 8. Body mass index 23.91 (3.83) 26.07 (4.75)   
  1. aMeasure of the severity of psychopathology. bGlobal index of functioning. cDrug adverse effect scales.